4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment: SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program

Guohong Han; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J. Ross; Shukui Qin; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Jordi Bruix

doi:10.1016/j.jvir.2018.01.420

4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment: SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program

Guohong Han, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Masatoshi Kudo, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Jordi Bruix

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	S162-S163
Journal	Journal of Vascular and Interventional Radiology
Volume	29
Issue number	4, Supplement
Early online date	1 Mar 2018
DOIs	https://doi.org/10.1016/j.jvir.2018.01.420
Publication status	Published - Apr 2018

Access to Document

10.1016/j.jvir.2018.01.420

Cite this

Han, G., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Yokosuka, O., Rosmorduc, O., Breder, V., Gerolami, R., Masi, G., Ross, P. J., Qin, S., Song, T., Bronowicki, J.-P., Ollivier-Hourmand, I., Kudo, M., LeBerre, M.-A., Baumhauer, A., Meinhardt, G., & Bruix, J. (2018). 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment: SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program. Journal of Vascular and Interventional Radiology, 29(4, Supplement), S162-S163. https://doi.org/10.1016/j.jvir.2018.01.420

Han, Guohong ; Merle, Philippe ; Granito, Alessandro et al. / 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment : SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program. In: Journal of Vascular and Interventional Radiology. 2018 ; Vol. 29, No. 4, Supplement. pp. S162-S163.

@article{6ef08d1a746e45c3991b2223531fc66e,

title = "4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment: SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program",

author = "Guohong Han and Philippe Merle and Alessandro Granito and Yi-Hsiang Huang and Gy{\"o}rgy Bodoky and Osamu Yokosuka and Olivier Rosmorduc and Valeriy Breder and Ren{\'e} Gerolami and Gianluca Masi and Ross, {Paul J.} and Shukui Qin and Tianqiang Song and Jean-Pierre Bronowicki and Isabelle Ollivier-Hourmand and Masatoshi Kudo and Marie-Aude LeBerre and Annette Baumhauer and Gerold Meinhardt and Jordi Bruix",

year = "2018",

month = apr,

doi = "10.1016/j.jvir.2018.01.420",

language = "English",

volume = "29",

pages = "S162--S163",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "4, Supplement",

}

Han, G, Merle, P, Granito, A, Huang, Y-H, Bodoky, G, Yokosuka, O, Rosmorduc, O, Breder, V, Gerolami, R, Masi, G, Ross, PJ, Qin, S, Song, T, Bronowicki, J-P, Ollivier-Hourmand, I, Kudo, M, LeBerre, M-A, Baumhauer, A, Meinhardt, G & Bruix, J 2018, '4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment: SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program', Journal of Vascular and Interventional Radiology, vol. 29, no. 4, Supplement, pp. S162-S163. https://doi.org/10.1016/j.jvir.2018.01.420

4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment: SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program. / Han, Guohong; Merle, Philippe; Granito, Alessandro et al.
In: Journal of Vascular and Interventional Radiology, Vol. 29, No. 4, Supplement, 04.2018, p. S162-S163.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment

T2 - SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program

AU - Han, Guohong

AU - Merle, Philippe

AU - Granito, Alessandro

AU - Huang, Yi-Hsiang

AU - Bodoky, György

AU - Yokosuka, Osamu

AU - Rosmorduc, Olivier

AU - Breder, Valeriy

AU - Gerolami, René

AU - Masi, Gianluca

AU - Ross, Paul J.

AU - Qin, Shukui

AU - Song, Tianqiang

AU - Bronowicki, Jean-Pierre

AU - Ollivier-Hourmand, Isabelle

AU - Kudo, Masatoshi

AU - LeBerre, Marie-Aude

AU - Baumhauer, Annette

AU - Meinhardt, Gerold

AU - Bruix, Jordi

PY - 2018/4

Y1 - 2018/4

U2 - 10.1016/j.jvir.2018.01.420

DO - 10.1016/j.jvir.2018.01.420

M3 - Meeting abstract

SN - 1051-0443

VL - 29

SP - S162-S163

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

IS - 4, Supplement

ER -

Han G, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O et al. 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment: SIR 2018 Annual Scientific Meeting ProgramSIR 2018 Annual Scientific Meeting Program. Journal of Vascular and Interventional Radiology. 2018 Apr;29(4, Supplement):S162-S163. Epub 2018 Mar 1. doi: 10.1016/j.jvir.2018.01.420